With obesity and diabetes reaching epidemic proportions worldwide, pharmaceutical companies are racing to develop more effective, accessible, and long-term treatment solutions.
The industry isn't a winner-takes-all market. In fact, competition will inevitably emerge starting in 2026, but that's okay in a fast-growing market like this. Both Novo and Eli will lose market share, yet continue growing.
The industry isn't a winner-takes-all market. In fact, competition will inevitably emerge starting in 2026, but that's okay in a fast-growing market like this. Both Novo and Eli will lose market share, yet continue growing.
Probably, as more competitors get the chance to compete.